+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Canada Pharmaceutical Market Size, Share & Trends Analysis Report by Drug Type, Product (Branded), Type (Prescription, OTC), Disease (Cancer), Route of Administration, Formulation, Age Group, End-use with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 119 Pages
  • May 2025
  • Region: Canada
  • Grand View Research
  • ID: 5943938
The Canada Pharmaceutical Market was valued at USD 51.56 billion in 2024, and is projected to reach USD 76.9 billion by 2030, rising at a CAGR of 7.00%. Several driving factors influence this significant and highly regulated industry. One of the primary drivers is Canada's aging population. With a growing number of seniors, there's a heightened demand for pharmaceuticals and healthcare services. For example, medications for conditions like osteoarthritis and Alzheimer's are in high demand due to the aging demographic.

Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.

Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.

Canada Pharmaceutical Market Report Highlights

  • By disease, the cancer segment led the market with the largest revenue share of 18.1% in 2024, attributed to the increasing prevalence of cancer and the ongoing development of advanced treatments.
  • The parenteral segment is set to experience the fastest growth during the forecast period, fueled by the increasing demand for injectable medications.
  • By formulation, the tablets segment accounted for the largest market share in 2024 due to their convenience, affordability, and ease of administration.
  • The sprays segment is anticipated to grow at the fastest CAGR from 2025 to 2030, propelled by their user-friendly nature and precise dosing capabilities.
  • By end use, the hospitals segment held the largest market share in 2024, propelled by the increasing number of hospitals, leading to higher demand for pharmaceutical drugs to treat various medical conditions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.2.2. Product
1.2.3. Type
1.2.4. Disease
1.2.5. Route of Administration
1.2.6. Formulation
1.2.7. Age Group
1.2.8. End Use
1.2.9. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Type Outlook
2.2.2. Product Outlook
2.2.3. Type Outlook
2.2.4. Disease Outlook
2.2.5. Route of Administration Outlook
2.2.6. Formulation Outlook
2.2.7. Age Group Outlook
2.2.8. End Use Outlook
2.3. Competitive Scenario
Chapter 3. Canada Pharmaceutical Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Canada Pharmaceutical Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Canada Pharmaceutical Market: Drug Type Business Analysis
4.1. Drug Type Segment Dashboard
4.2. Canada Pharmaceutical Market: Drug Type Movement Analysis
4.3. Canada Pharmaceutical Market Size & Trend Analysis, By Drug Type, 2018 to 2030 (USD Billion)
4.4. Biologics & Biosimilars (Large Molecules)
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.2. Monoclonal Antibodies
4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.3. Vaccines
4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.4. Cell & Gene Therapy
4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.4.5. Others
4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
4.5. Conventional Drugs (Small Molecules)
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 5. Canada Pharmaceutical Market: Product Business Analysis
5.1. Product Segment Dashboard
5.2. Canada Pharmaceutical Market: Product Movement Analysis
5.3. Canada Pharmaceutical Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Billion)
5.4. Branded
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
5.5. Generics
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 6. Canada Pharmaceutical Market: Type Business Analysis
6.1. Type Segment Dashboard
6.2. Canada Pharmaceutical Market: Type Movement Analysis
6.3. Canada Pharmaceutical Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Billion)
6.4. Prescription
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
6.5. OTC
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 7. Canada Pharmaceutical Market: Disease Business Analysis
7.1. Disease Segment Dashboard
7.2. Canada Pharmaceutical Market: Disease Movement Analysis
7.3. Canada Pharmaceutical Market Size & Trend Analysis, By Disease, 2018 to 2030 (USD Billion)
7.4. Cardiovascular diseases
7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.5. Cancer
7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.6. Diabetes
7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.7. Infectious diseases
7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.8. Neurological Disorders
7.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.9. Respiratory diseases
7.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.10. Autoimmune diseases
7.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.11. Mental health disorders
7.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.12. Gastrointestinal disorders
7.12.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.13. Women’s Health Diseases
7.13.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.14. Genetic and Rare genetic diseases
7.14.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.15. Dermatological conditions
7.15.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.16. Obesity
7.16.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.17. Renal diseases
7.17.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.18. Liver conditions
7.18.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.19. Hematological disorders
7.19.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.20. Eye conditions
7.20.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.21. Infertility conditions
7.21.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.22. Endocrine disorders
7.22.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.23. Allergies
7.23.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
7.24. Others
7.24.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 8. Canada Pharmaceutical Market: Route of Administration Business Analysis
8.1. Route of Administration Segment Dashboard
8.2. Canada Pharmaceutical Market: Route of Administration Movement Analysis
8.3. Canada Pharmaceutical Market Size & Trend Analysis, By Route of Administration, 2018 to 2030 (USD Billion)
8.4. Oral
8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.5. Topical
8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6. Parenteral
8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6.2. Intravenous
8.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.6.3. Intramuscular
8.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.7. Inhalations
8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
8.8. Other Routes of Administration
8.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 9. Canada Pharmaceutical Market: Formulation Business Analysis
9.1. Formulation Segment Dashboard
9.2. Canada Pharmaceutical Market: Formulation Movement Analysis
9.3. Canada Pharmaceutical Market Size & Trend Analysis, By Formulation, 2018 to 2030 (USD Billion)
9.4. Tablets
9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.5. Capsules
9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.6. Injectable
9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.7. Sprays
9.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.8. Suspensions
9.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.9. Powders
9.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
9.10. Other Formulations
9.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 10. Canada Pharmaceutical Market: Age Group Business Analysis
10.1. Age Group Segment Dashboard
10.2. Canada Pharmaceutical Market: Age Group Movement Analysis
10.3. Canada Pharmaceutical Market Size & Trend Analysis, By Age Group, 2018 to 2030 (USD Billion)
10.4. Children & Adolescents
10.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
10.5. Adults
10.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
10.6. Geriatric
10.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 11. Canada Pharmaceutical Market: End Use Business Analysis
11.1. End Use Segment Dashboard
11.2. Canada Pharmaceutical Market: End Use Movement Analysis
11.3. Canada Pharmaceutical Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Billion)
11.4. Hospitals
11.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
11.5. Clinics
11.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
11.6. Others
11.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
Chapter 12. Competitive Landscape
12.1. Recent Developments & Impact Analysis, By Key Market Participants
12.2. Company/ Competition Categorization
12.3. Vendor Landscape
12.3.1. Key Company Heat Map Analysis, 2024
12.4. Company Profiles
12.4.1. F. Hoffmann-La Roche Ltd
12.4.1.1. Company Overview
12.4.1.2. Financial Performance
12.4.1.3. Product Benchmarking
12.4.1.4. Strategic Initiatives
12.4.2. Novartis AG
12.4.2.1. Company Overview
12.4.2.2. Financial Performance
12.4.2.3. Product Benchmarking
12.4.2.4. Strategic Initiatives
12.4.3. GSK plc
12.4.3.1. Company Overview
12.4.3.2. Financial Performance
12.4.3.3. Product Benchmarking
12.4.3.4. Strategic Initiatives
12.4.4. Pfizer Inc.
12.4.4.1. Company Overview
12.4.4.2. Financial Performance
12.4.4.3. Product Benchmarking
12.4.4.4. Strategic Initiatives
12.4.5. Merck & Co., Inc.
12.4.5.1. Company Overview
12.4.5.2. Financial Performance
12.4.5.3. Product Benchmarking
12.4.5.4. Strategic Initiatives
12.4.6. AstraZeneca
12.4.6.1. Company Overview
12.4.6.2. Financial Performance
12.4.6.3. Product Benchmarking
12.4.6.4. Strategic Initiatives
12.4.7. Johnson & Johnson Services, Inc.
12.4.7.1. Company Overview
12.4.7.2. Financial Performance
12.4.7.3. Product Benchmarking
12.4.7.4. Strategic Initiatives
12.4.8. Sanofi
12.4.8.1. Company Overview
12.4.8.2. Financial Performance
12.4.8.3. Product Benchmarking
12.4.8.4. Strategic Initiatives
12.4.9. Eli Lilly and Company
12.4.9.1. Company Overview
12.4.9.2. Financial Performance
12.4.9.3. Product Benchmarking
12.4.9.4. Strategic Initiatives
12.4.10. AbbVie Inc.
12.4.10.1. Company Overview
12.4.10.2. Financial Performance
12.4.10.3. Product Benchmarking
12.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Canada Pharmaceutical Market, By Drug Type, 2018-2030 (USD Billion)
Table 4 Canada Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 5 Canada Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 6 Canada Pharmaceutical Market, By Disease, 2018-2030 (USD Billion)
Table 7 Canada Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 8 Canada Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 9 Canada Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 10 Canada Pharmaceutical Market, By End Use, 2018-2030 (USD Billion)
List of Figures
Figure 1 Market Research Process
Figure 2 Data Triangulation Techniques
Figure 3 Primary Research Pattern
Figure 4 Primary Interviews
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 QFD Modeling for Market Share Assessment
Figure 8 Market Formulation & Validation
Figure 9 Canada Pharmaceutical Market: Market Outlook
Figure 10 Canada Pharmaceutical Competitive Insights
Figure 11 Parent Market Outlook
Figure 12 Related/Ancillary Market Outlook
Figure 13 Penetration and Growth Prospect Mapping
Figure 14 Industry Value Chain Analysis
Figure 15 Canada Pharmaceutical Market Driver Impact
Figure 16 Canada Pharmaceutical Market Restraint Impact
Figure 17 Canada Pharmaceutical Market Strategic Initiatives Analysis
Figure 18 Canada Pharmaceutical Market: Drug Type Movement Analysis
Figure 19 Canada Pharmaceutical Market: Drug Type Outlook and Key Takeaways
Figure 20 Biologics & Biosimilars (Large Molecules) Market Estimates and Forecast, 2018-2030
Figure 21 Monoclonal Antibodies Market Estimates and Forecast, 2018-2030
Figure 22 Vaccines Market Estimates and Forecast, 2018-2030
Figure 23 Cell & Gene Therapy Market Estimates and Forecast, 2018-2030
Figure 24 Others Market Estimates and Forecast, 2018-2030
Figure 25 Conventional Drugs (Small Molecules) Market Estimates and Forecast, 2018-2030
Figure 26 Canada Pharmaceutical Market: Product Movement Analysis
Figure 27 Canada Pharmaceutical Market: Product Outlook and Key Takeaways
Figure 28 Branded Market Estimates and Forecast, 2018-2030
Figure 29 Generics Market Estimates and Forecast, 2018-2030
Figure 30 Canada Pharmaceutical Market: Type Movement Analysis
Figure 31 Canada Pharmaceutical Market: Type Outlook and Key Takeaways
Figure 32 Prescription Market Estimates and Forecast, 2018-2030
Figure 33 OTC Market Estimates and Forecast, 2018-2030
Figure 34 Canada Pharmaceutical Market: Disease Movement Analysis
Figure 35 Canada Pharmaceutical Market: Disease Outlook and Key Takeaways
Figure 36 Cardiovascular diseases Market Estimates and Forecast, 2018-2030
Figure 37 Cancer Market Estimates and Forecast, 2018-2030
Figure 38 Diabetes Market Estimates and Forecast, 2018-2030
Figure 39 Infectious diseases Market Estimates and Forecast, 2018-2030
Figure 40 Neurological disorders Market Estimates and Forecast, 2018-2030
Figure 41 Respiratory diseases Market Estimates and Forecast, 2018-2030
Figure 42 Autoimmune diseases Market Estimates and Forecast, 2018-2030
Figure 43 Mental health disorders Market Estimates and Forecast, 2018-2030
Figure 44 Gastrointestinal disorders Market Estimates and Forecast, 2018-2030
Figure 45 Women’s Health Diseases Market Estimates and Forecast, 2018-2030
Figure 46 Genetic and Rare genetic diseases Market Estimates and Forecast, 2018-2030
Figure 47 Dermatological conditions Market Estimates and Forecast, 2018-2030
Figure 48 Obesity Market Estimates and Forecast, 2018-2030
Figure 49 Renal diseases Market Estimates and Forecast, 2018-2030
Figure 50 Liver conditions Market Estimates and Forecast, 2018-2030
Figure 51 Hematological disorders Market Estimates and Forecast, 2018-2030
Figure 52 Eye conditions Market Estimates and Forecast, 2018-2030
Figure 53 Infertility conditions Market Estimates and Forecast, 2018-2030
Figure 54 Endocrine disorders Market Estimates and Forecast, 2018-2030
Figure 55 Allergies Market Estimates and Forecast, 2018-2030
Figure 56 Others Market Estimates and Forecast, 2018-2030
Figure 57 Canada Pharmaceutical Market: Route of Administration Movement Analysis
Figure 58 Canada Pharmaceutical Market: Route of Administration Outlook and Key Takeaways
Figure 59 Oral Market Estimates and Forecast, 2018-2030
Figure 60 Topical Market Estimates and Forecast, 2018-2030
Figure 61 Parenteral Market Estimates and Forecast, 2018-2030
Figure 62 Intravenous Market Estimates and Forecast, 2018-2030
Figure 63 Intramuscular Market Estimates and Forecast, 2018-2030
Figure 64 Inhalations Market Estimates and Forecast, 2018-2030
Figure 65 Other Routes of Administration Market Estimates and Forecast, 2018-2030
Figure 66 Canada Pharmaceutical Market: Formulation Movement Analysis
Figure 67 Canada Pharmaceutical Market: Formulation Outlook and Key Takeaways
Figure 68 Tablets Market Estimates and Forecast, 2018-2030
Figure 69 Capsules Market Estimates and Forecast, 2018-2030
Figure 70 Injectable Market Estimates and Forecast, 2018-2030
Figure 71 Sprays Market Estimates and Forecast, 2018-2030
Figure 72 Suspensions Market Estimates and Forecast, 2018-2030
Figure 73 Powders Market Estimates and Forecast, 2018-2030
Figure 74 Other Formulations Market Estimates and Forecast, 2018-2030
Figure 75 Canada Pharmaceutical Market: Age Group Movement Analysis
Figure 76 Canada Pharmaceutical Market: Age Group Outlook and Key Takeaways
Figure 77 Children & Adolescents Market Estimates and Forecast, 2018-2030
Figure 78 Adults Market Estimates and Forecast, 2018-2030
Figure 79 Geriatric Market Estimates and Forecast, 2018-2030
Figure 80 Canada Pharmaceutical Market: End Use Movement Analysis
Figure 81 Canada Pharmaceutical Market: End Use Outlook and Key Takeaways
Figure 82 Hospitals Market, 2018-2030 (USD Billion)
Figure 83 Clinics Market, 2018-2030 (USD Billion)
Figure 84 Others Market, 2018-2030 (USD Billion)

Companies Mentioned

The major companies featured in this Canada Pharmaceutical market report include:
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GSK plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca
  • Johnson & Johnson Services, Inc.
  • Sanofi
  • Eli Lilly and Company
  • AbbVie Inc.

Table Information